PetMed Express
PetMed Express' revenue fell 21.1% to $179 million in fiscal 2026. Its operating margin was −32.8%, down from −0.7% a year earlier. Free cash flow was −$33 million. It paid out $0 million in dividends and buybacks. The diluted share count rose 1.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2017 to 2023, earnings per share fell 22.7% a year and net income 22.6% a year, with the share count about the same. PetMed Express then lost money in fiscal 2024, 2025 and 2026.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 111 | 104 | 55 | 55 | 21 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 2.7x | 2.3x | 1.3x | 1.3x | 0.8x |
| Quick ratio | 2.1x | 1.9x | 0.9x | 1.0x | 0.6x |
Cash flow
Projections
Project PetMed Express' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $43,750 of PetMed Express shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Zyman Stephannie Matz10% owner | Bought | 25,000 | $1.75 | $43,750 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 10.6% | −17.4% | −39.6% |
| Altman Z'' | 3.27 | 3.51 | −4.59 |
| Accruals ratio | −7.0% | −6.9% | −25.1% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put PetMed Express side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| PetMed Express | FY26 | −21.1% | −32.8% | −18.4% | — | — | — | |
| GrowGeneration | FY25 | −14.4% | −15.8% | — | −35.1% | — | 5 | Compare |
| Envela | FY25 | 33.6% | 7.5% | 0.6% | 27.1% | −0.4x | 6 | Compare |
| ThredUp | FY25 | 19.5% | −7.0% | 0.1% | −54.2% | — | 4 | Compare |
| Rent the Runway | FY25 | 7.7% | −17.4% | −21.9% | −77.8% | — | 6 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 249 | 274 | 283 | 284 | 304 | 272 | 248 | 274 | 227 | 179 |
| Revenue growth | 6.2% | 9.9% | 3.5% | 0.2% | 6.8% | −10.3% | −9.1% | 10.7% | −17.2% | −21.1% |
| Gross profit | 79 | 98 | 95 | 81 | 84 | 77 | 76 | 85 | 69 | 50 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 38 | 52 | 46 | 31 | 30 | 24 | 6 | −8 | −2 | −59 |
| Net income | 24 | 37 | 38 | 26 | 24 | 19 | 5 | −8 | −6 | −57 |
| Diluted EPS (US$) | 1.17 | 1.82 | 1.84 | 1.29 | 1.19 | 0.92 | 0.25 | −0.37 | −0.30 | −2.74 |
| Diluted shares (millions) | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 21 | 21 |
| Cash flow | ||||||||||
| Cash from operations | 47 | 37 | 45 | 39 | 40 | 18 | 28 | 4 | 5 | −28 |
| Capital expenditure | 11 | 1 | 1 | 2 | 2 | 2 | 5 | 4 | 5 | 5 |
| Free cash flow | 37 | 37 | 45 | 37 | 38 | 17 | 23 | −0 | −0 | −33 |
| Dividends paid | 16 | 18 | 22 | 22 | 23 | 24 | 24 | 12 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36 | 0 | 0 |
| Stock-based compensation | 2 | 3 | 3 | 3 | 3 | 4 | 7 | 7 | −7 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 59 | 78 | 100 | 104 | 119 | 111 | 104 | 55 | 55 | 21 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 113 | 135 | 154 | 155 | 188 | 180 | 168 | 170 | 149 | 81 |
| Total liabilities | 19 | 19 | 20 | 25 | 46 | 56 | 58 | 73 | 64 | 52 |
| Shareholders' equity | 93 | 116 | 135 | 120 | 125 | 123 | 110 | 97 | 85 | 29 |
| Margins and ratios | ||||||||||
| Gross margin | 31.8% | 35.7% | 33.6% | 28.6% | 27.8% | 28.3% | 30.9% | 30.9% | 30.5% | 28.1% |
| Operating margin | 15.0% | 19.0% | 16.3% | 10.9% | 10.1% | 8.9% | 2.4% | −3.0% | −0.7% | −32.8% |
| Net margin | 9.6% | 13.6% | 13.3% | 9.1% | 7.9% | 6.9% | 2.1% | −2.7% | −2.8% | −32.0% |
| Free cash flow margin | 14.7% | 13.4% | 15.7% | 12.9% | 12.4% | 6.2% | 9.1% | −0.1% | −0.2% | −18.4% |
| Rule of 40 (growth + FCF margin) | 20.9% | 23.3% | 19.2% | 13.1% | 19.2% | −4.2% | 0.0% | 10.6% | −17.4% | −39.6% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 27.0% | 35.7% | 30.1% | 20.3% | 19.5% | 15.1% | 4.4% | −7.2% | −6.9% | −100.4% |
| Return on assets | 23.5% | 30.1% | 26.1% | 16.7% | 13.9% | 10.2% | 3.0% | −4.4% | −3.9% | −49.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |